Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TSOI is making a demand for the immediate turnover of documentation regarding the withdrawals of aliquots from Master Cell Bank One, their transportation, storage, processing for assay, and use in administering them to patients. TSOI also expresses grave concerns about the proper documentation, process, and control of living drugs based on testimonies of doctors and the lack of documentation or written disclosures by UM and Jadi Cell LLC.
The tone of the SEC filings (with letters) suggests that TSOI believes that University Of Miami, Dr. Ricordi, Dr.Patel, and Niel Riordan may be hiding something. However, it is clear that TSOI is asking for something specific or simply demanding that UM comply with their request for documentation.
keep waiting like all of US!
$TSOI Oh, wow, what a brilliant math problem! I mean, who doesn't love doing math to figure out someone else's financial losses, am I right? And of course, we can't forget to mention that TSOI touched .0063 on Thursday, because that's obviously the most important thing to focus on here. I'm sure you guys would just love to hear all about it and have a good laugh at someone else's expense. How delightful!
$TSOI, under the leadership of Tim G Dixon, has achieved remarkable success in the biotech industry. Notably, they have accrued a mere $17.5 million in debt over a period of 12 years without resorting to any reverse splits. This is a testament to the company's financial prudence and stability.
Moreover, TSOI is on the cusp of achieving yet another milestone with their second Phase 3 asset expected to be announced this week. What's impressive is that this asset may have advanced from pre-clinicals straight to Phase 3, potentially saving TSOI millions of dollars. When you consider the number of drugs in the Jadi pipeline, the potential savings multiply significantly.
Some of the diseases that TSOI is working on, such as emphezema, bronchitis, ASTHMA, pulmonary fibrosis, ALS, and COPD, hold immense promise for the company's future. With their exceptional track record and innovative approach, $TSOI is poised to become one of the most exciting biotechs of this generation.
$TSOI CEO of TSOI is expressing confidence in their own in-house cGMP (current Good Manufacturing Practice) contract manufacturing source, and indicating that they do not require the services of any other external parties. The CEO also suggests that TSOI has been treating all the people they work with well, and implies that they will continue to do so in the future.
In addition, the statement reveals that TSOI subsidiary Allogen Biologics will be responsible for housing all of the cell banks for the company's cellular products. This could be interpreted as a sign of TSOI's commitment to their cellular products and their desire to maintain control over their manufacturing processes.
$TSOI has been showing strong momentum and has recently been making significant gains. The company has a promising product pipeline and a strong management team. With its innovative solutions and growing market demand, $TSOI has the potential to become a major player in its industry.
$TSOI This is EXACTLY what Slummy/??&co were doing early summer of 2021. Pumping to dump. Except this time, they won’t be “saved by the bell”, oh no, the bell, it tolls for thee.
When investors post information on social media, don’t omit pertinent information. Provide reason and verifiable factual evidence in support of your opinions. Show your math.
Link to substance. Whether they be positive or negative. It’s a federal crime to profit off the backs of other investors by purposefully publishing manipulative statements. True.
Think this is a game? That YOU, the manipulators of the float, the synthetic shirts, are untouchable? That YOU can steal from innocent victims, and get away with it?
??hmmm
KNOW WHAT YOU OWN.????
Read everything.
$TSOI Breathe Biologics Inc. already has an IND (Investigational New Drug) study for COPD (Chronic Obstructive Pulmonary Disease) using TSOI (Tissue Repair Company) technology. It's interesting that TSOI plans to supplement the IND study for COPD with phase 3 data from ARDS (Acute Respiratory Distress Syndrome) before actually starting the phase 1/2b upgrade to phase 3. This may suggest that TSOI is trying to expedite the process by using data from a related condition to support the safety and efficacy of their technology. It will be interesting to watch and see how the study progresses.
$TSOI It seems that the Phase 3 IND approved to treat covid-19 ARDS is based on scientific evidence that the msc's used in Phase 2b were standard msc's of unknown tissue origin. The data regarding the msc's is contained in the drug master file, and the company that made the statement owns the exclusive rights to use this data for lung and brain-related applications. The statement by CEO Tim Dixon suggests that the company is not relying on anything except the clinical data already available to them in the DMF, and they have used this data in the past for other conditions like CTE and COPD, and they plan to use it for future applications as well.
$TSOI Great TSOI news day…tough to top. ReStem gets a USPTO “beat down”, and Icon Capital represents TSOI.
Not bad, Faithful! ??
It's exciting to see TSOI making positive strides, including the recent USPTO decision against ReStem and the representation by Icon Capital. Their expertise in trading on both domestic and international markets is valuable, and their commitment to sourcing liquidity while maintaining quality execution is impressive.
Overall, these developments are fantastic news for TSOI and its investors.
$TSOI Tim Dixon, Thomas Ichim and the team of the very talented individuals they have assembled have shown great amount patience over these last few years.
Generating enormous success not only in developing novel science (in-house) at little cost, but to advance it. And then to advance it into actual human beings, with terrible afflictions, fatal diseases; successfully. These are not small things. And that’s no surprise at the source, these are not small minded men (and Famela ??).
Knowledgeable investors should take heart in what they see with their own two eyes. Unrivaled, incomparable production, shadowed by unrelenting attacks in multimedia against good men and women simply vying to do good for humanity. And even under such conditions, they have thwarted these veiled attacks, with vigor. Not only surviving, but thriving.
It is a testament to the dedication and perseverance of Tim Dixon, Thomas Ichim, and their team that they have been able to achieve such remarkable success in the field of biomedical research, particularly in developing therapies for fatal diseases. Their accomplishments are even more impressive given the challenges they have faced, including media attacks and scrutiny. Their ability to overcome these challenges and continue to produce innovative and life-saving treatments is truly admirable. Investors who recognize the value of their work should have confidence in their future success.
$TSOI I agree that there is nothing wrong with reaching out to the University of Miami and asking questions. They likely have access to more information than we do regarding the events and circumstances surrounding TSOI, and their lack of response does speak volumes.
However, I believe that TSOI has advanced beyond the 176 material patent, and their work has shown success outside of any phase 3 trial. With over 100 fully treated patients and no fatalities, their record of success is impressive. They are advancing the science and proving the safety and efficacy of their UC – MSC in real-world applications.
Despite the unfortunate situation with the University of Miami, TSOI holds the key to its own future without any middlemen or partners to interfere. They have Campbell neurosciences, ALLO, RENO, and BRTH, which are all showing promise. With no more obstacles in their way, TSOI can move forward relentlessly.
I believe that the issues with the University of Miami will sort themselves out in time, and while they stand waiting for something to happen, TSOI continues to make progress. Campbell neurosciences is fully matured, RENO has their personnel and structure in place, and now BRTH has their landing page/website out. With Banerji on the SAB and Thomas Ichim as CEO, TSOI is poised for success in the COPD space.
Overall, TSOI's work is transcending the typical pathway for a growing biotech company. They are selflessly advancing the science and benefitting from the proof of their safety and efficacy in real-world applications. I look forward to seeing what they do next.
$TSOI it sounds like the University of Miami is in quite a pickle! Maybe they're just waiting for their lucky star to come along and fix things for them. But in the meantime, it's great to hear that TSOI is moving forward relentlessly, like a shark in a business suit. And with all these brainy scientists on board, I have no doubt they'll come up with some truly mind-boggling breakthroughs. So let's sit back, relax, and watch as TSOI takes the world by storm! Just don't forget to buckle up, because it's going to be one wild ride.
$TSOI
It is true that finding an OTC biotech company with 75+ IP and 35 issued patents is a very difficult task for a wallstreet financial analyst or hedge fund manager. This level of intellectual property indicates that TSOI has invested significant resources in research and development and has a strong portfolio of innovative technology. This intellectual property portfolio can serve as a barrier to entry for competitors and provides a significant advantage in the market.
Additionally, the absence of reverse splits and toxic debt is a positive indicator of the financial health of TSOI. Reverse splits and toxic debt are often used by struggling companies as a last resort to raise capital, which can be detrimental to shareholder value. Therefore, the absence of these negative financial practices is a strong indication that the company is well managed and has a sustainable business model.
Moreover, the fact that TSOI has spin-offs, supreme voting control, and dividend offerings indicates that the company is focused on long-term growth and creating value for its shareholders. This is further supported by the successful treatment of over 100 RTT patients, demonstrating the efficacy of the company's technology and its potential for commercial success.
Finally, the FDA validated living CTE diagnostic and suicidal ideation diagnostic demonstrate the company's commitment to developing innovative solutions to critical medical problems. This indicates that TSOI is not only focused on financial success but also on making a positive impact on the world through its life saving biologics technology.
sometimes, even though a flattened out technical chart may indicate a potential bottom, it doesn't guarantee a rebound in stock price. Additionally, the conversion of patents into revenue is not always a straightforward process and may take time and resources to accomplish. Nonetheless, with the right strategies and execution, $TSOI has the potential to capitalize on its intellectual property and drive growth in the future.
Oh, of course Tim is just so 'devoted' to shareholder value, I mean, he's only the largest shareholder in the company! How could we ever doubt his altruistic motivations? Clearly, his actions are driven solely by a deep and abiding concern for the well-being of all those shareholders...right. Next!
$TSOI Oh, of course, Tim Dixon, the CEO of $TSOI, is clearly a shining example of a CEO who is absolutely devoted to shareholder value. I mean, just look at how he's consistently put their interests above his own, and how he's always been transparent about his dedication to maximizing shareholder returns. It's almost like he's a saint or something. I'm sure he's demonstrated this unwavering devotion to shareholder value at every opportunity, and has never said or done anything that would suggest otherwise. After all, why would anyone doubt the word of a CEO?
$TSOI Tim Dixon is just the epitome of honesty and integrity. I mean, he's definitely not a fraud who's been scamming investors left and right, right? And all those possibilities made about EUA and Costco and 600 stores and Phase 3 - they're clearly just the gospel truth. I'm sure you can take everything he says at face value and not worry about any of it being a big, fat lie. There is no harm in keeping everyone informed about the current events on company forum.
$TSOI Oh wow, $TSOI, what an amazing investment opportunity! I mean, who wouldn't want to put their hard-earned money into a company led by such a erudite/learned guy like Tim Dixon? he's completely devoted to shareholder value..And let's not forget how he's a total role model for his grandson son, little Timmy, who I'm sure is just bursting with pride to have such an upstanding grandfather who is considered modern day genius what could be more inspiring than that? So yeah, lets all watch $TSOI skyrocket to the moon!
1. Therapeutic Solutions International (TSOI) announced the launching of the Veltmeyer Institute for Advanced Biologics (VIAB).
2. VIAB provides allogeneic stem cells that have been cleared by the FDA for clinical trials. The cells are provided by JadiCell.
3. It is interesting to note that the Veltmeyer Institute leverages the experience of Dr. James Veltmeyer, who has treated over 100 patients under the Right to Try Law in collaboration with TSOI and other biotechnology companies.
it looks like the RTT calendar is playing hooky. Maybe it's off somewhere getting a much-needed break after all that life-saving work. But in the meantime, let's focus on this OTC/Oink that's as rare as a unicorn sighting. With 73 filed patents, 36 published patents, and 4 issued patents, this company has more intellectual property than Einstein had crazy hair days. And to top it off, they haven't done any RS-ing, so their shares are as stable as a table with four legs. With four subsidiaries, including one that's giving out free dividends like it's Halloween candy, this company is practically the Santa Claus of the stock market. And let's not forget that they're saving real lives. So while we may not be able to find that elusive RTT calendar, we can certainly find some solace in this company's incredible achievements. go $TSOI pps to go higher!
yeah! investing in a company with a history of fraud and disappointment is always a sound financial decision. I mean, who needs promising results and ethical leadership when you can just hand over your hard-earned money to a CEO who's more interested in lining his own pockets than delivering value to shareholders? And hey, even if the company crashes and burns, at least Tim Dixon's kids will be set for life, right? It's not like the rest of us have anything better to do with our money anyway. So yeah, what could go wrong? Absolutely nothing, I'm sure.
Oh sure, because it's totally normal for a CEO to scam people and then publicly mock and belittle them for their appearance. I mean, what could be more professional and respectable than fat-shaming someone you've already scammed? Clearly, Timmy Boy Dixon is a paragon of integrity and kindness.
$TSOI Today The results of treating seven Chronic traumatic encephalopathy (CTE) patients with JADICELLS submitted to FDA, are more than promising and shall help TSOI start the Phase 2a/2b or may be Phase 2 trial as well soon. the use of JADICELLS in medical treatments is a rapidly developing field
Dr. Ichim's success in selling Medistem Inc for $1.35 to Intrexon was a significant achievement in the biotech industry. The sale represented a substantial return on investment for Medistem's shareholders and demonstrated Dr. Ichim's business acumen and leadership skills. Following the sale, Dr. Ichim continued to work in the biotech industry, leveraging his expertise to help develop new therapies and improve patient outcomes.
It's exciting to think about the possibilities that could arise from JADICELLS in the field of regenerative medicine for Lung and Brain and much more in future
Therapeutic Solutions International, Inc is a publicly-traded company that focuses on developing and commercializing innovative therapies and technologies in the areas of regenerative medicine, nutraceuticals, and life sciences. The company's management team and Scientific Advisory Board include individuals with expertise in these areas.
Therapeutic Solutions International, Inc has spun off four privately held subsidiaries, which are focused on developing therapies and technologies in various areas such as cancer immunotherapy, regenerative medicine, and neurodegenerative diseases. The company has also filed a significant number of patents, including issued patents, and has a growing nutraceutical sales business that no other biotech companies can even match..
Tim Dixon has been actively involved in the research and development of natural molecules that can be used as alternatives to synthetic drugs in treating chronic diseases.
He has over 20 years of experience in the biotechnology industry and has worked with several leading pharmaceutical companies to develop novel therapies for various diseases.
Tim Dixon's expertise lies in the field of biologics and neutraceuticals, which are natural products that have therapeutic benefits.
He has a deep understanding of the biology of chronic diseases such as cancer, Alzheimer's, Parkinson's, and cardiovascular diseases, and uses this knowledge to develop targeted therapies that are effective and safe.
Tim Dixon is committed to finding natural solutions to chronic diseases that not only treat the symptoms but also address the root cause of the disease.
He believes in using evidence-based approaches to develop therapies and collaborates with leading researchers and clinicians to ensure that his therapies are scientifically sound and clinically effective.
Tim Dixon's goal is to improve the lives of millions of people suffering from chronic diseases by providing them with safe, effective, and affordable therapies.
Oh, absolutely! who needs proper scientific evidence when you've got patents, am I right? ????? And of course, the fact that other companies are trading at higher market capitalization is a foolproof indicator of TSOI's success. ?? Who needs logic and critical thinking when you've got emojis? ??
The Emerging Research On Exosomes Is Filled With Promise, But Still New
The Emerging Research On Exosomes Is Filled With Promise, But Still New
While often confused with stem cells, exosomes are not cells. They are the smallest of all Extracellular Vesicles (EVs) – the various particles cells secrete to send messages and materials to each other. EVs are how cells tell each other to reproduce, differentiate into specific cells, repair, and so on. It’s also how cells pass along proteins, lipids, DNA, RNA, and other materials that the receiving cell might need to carry out those functions.
EVs may have the potential to reduce inflammation, repair damaged tissue, and otherwise help cells regenerate and heal.
Their ability to carry cargo to a cell has also attracted interest from biopharmaceutical developers who are looking into using EVs as a delivery mechanism for therapeutics. If these developers can engineer EVs that carry a specific drug to specific cells – like delivering chemotherapeutic agents to tumor cells – they could create more targeted treatments with fewer adverse reactions. Biotech companies are working on creating the technology necessary to reliably engineer exosomes to create potent and highly targeted treatments.
This field of study is still emerging and there is a lot that researchers still don’t yet know about EVs. A lot of the most promising data to come out about these messenger particles is from animal and cell culture studies. So a major hurdle the research still needs to overcome is whether those exciting findings will translate to human studies.
?? Hmm, I wonder if that's what Alexander Graham Bell's friends said when he patented the telephone. ?? But seriously, let's hope this patent turns out to be more hugely of commercial value to Big Pharma!
Yooperman...
It is certainly true that innovative products and patents can play a crucial role in the success of a company and its stock price. CEO Dixon's transparency and effective communication with shareholders on the company forum are also critical factors in building trust and confidence in the company.
Shareholders need to understand the company's vision, strategy, and progress towards its goals in order to make informed investment decisions. TSO forum provides all of us with regular updates and disclosures from the company, as well as a willingness to address concerns and answer questions from shareholders.
Ultimately, a combination of strong intellectual property, innovative products, and effective communication with shareholders can help TSOI build a strong reputation and drive long-term success. Its unheard of any other OTC company and even BIG pharma co ever attempted to this kind of approach where CEO spends time with shareholders. Its a great WIN-WIN proposition for TSOI and its shareholders.
Yooperman ..could not agree more....biotech companies because of the significant time and resources required for the development, testing, and approval of new drugs and therapies. Add on to it, approvals from the FDA (regulatory environment) for biotech companies can be challenging, Having said that... successful biotech companies have the potential for significant growth and can provide innovative solutions to some of the most pressing healthcare challenges facing society today
Well, you know what they say - good things come to those who wait! I'm just playing the long game with those 73 patents , you see. I figure if I wait long enough, they'll become valuable antiques and I can sell them for a fortune to some tech historian. Or, you know, I could just use them to wallpaper my office and impress visitors with my intellectual prowess. Either way, I'm not too worried about monetizing them right this second. Patience is a virtue, after all!
?? Hmm, let me consult my trusty Magic 8-Ball...
?? "Every Sign point to NO"
Good luck with your report! ????
???????????? As far I know only a Plumber certainly knows how to fix a leaky faucet and a broken heart!"
It's impressive to see that Therapeutic Solutions International Inc. has been able to secure 34 patents through the lengthy patent process. Patents are an important tool for protecting intellectual property and can help companies maintain a competitive edge in their respective industries. It's also worth noting that obtaining a patent is not an easy task and requires significant time and resources, including extensive research and development efforts.
Its an indication of a $TSOI's innovative capabilities and dedication to advancing their field of expertise. As you mentioned, the price of a company's products or services can reflect the value of their intellectual property and research efforts, making patents a valuable asset.
Overall, it's clear that Therapeutic Solutions International Inc. has put in a great deal of effort to secure these patents and should be commended for their dedication to innovation and intellectual property protection.
I'm keeping an eye out for those patent grants this summer! Here's hoping they roll in like a wave ?? and we can all kick back with a drink ?? on the beach ??? and bask in our intellectual property glory ??????"
Thank you so much Cents! ???? It feels like we've been holding on for dear life, but hey, at least our grip is still strong! ??????? Here's to us and our diamond hands! ????
kstock good to hear from you, getting the FDA/RTT's stamp of approval can be a real game-changer for otc biotech co like TSOI. It's like receiving shiny new badge of legitimacy.
getting FDA/RTT approval is not easy. So, if TSOI manages to jump through all the hoops and come out the other side with a thumbs-up from the regulatory gods, then stock price is going to skyrocket faster than Elon Musk's Tesla on Ludicrous Mode!